Sensei Biotherapeutics, Inc. announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody. Research will be conducted in the laboratory of Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs, to evaluate the underlying molecular mechanisms that enable SNS-101 to overcome myeloid cell-driven immunosuppression within the tumor microenvironment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.97 USD | -1.31% | -3.48% | +40.17% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.17% | 24.64M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics Inc. Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, A Conditionally Active VISTA-Blocking Antibody